Hepatitis C Testing, Status and Treatment among Marginalized People Who Use Drugs in an Inner City Setting: An Observational Cohort Study

References

• Aaron, S., McMahon, J. M., Milano, D., Torres, L., Clatts, M., Tortu, S., … Simm, M. (2008). Intranasal transmission of hepatitis C virus: Virological and clinical evidence. Clinical Infectious Diseases, 47(7), 931–934. doi:10.1086/591699
   PubMed Web of Science ®Google Scholar
• Antoniou, T., Zagorski, B., Loutfy, M. R., Strike, C., & Glazier, R. H. (2011). Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection. PLoS One, 6(6), e21748. doi:10.1371/journal.pone.0021748
   PubMed Web of Science ®Google Scholar
• Artenie, A. A., Bruneau, J., Lévesque, A., & Wansuanganyi, J.-M. B. (2014). Role of primary care providers in hepatitis C prevention and care: One step away from evidence-based practice. Canadian Family Physician Médecin de Famille Canadien, 60(10), 881–882, e468-70. doi:10.1016/j.drugalcdep.2014.11.011
   PubMed Web of Science ®Google Scholar
• Artenie, A. A., Jutras-Aswad, D., Roy, É., Zang, G., Bamvita, J.-M., Lévesque, A., & Bruneau, J. (2015). Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: Room for improvement. Journal of Viral Hepatitis, 22(10), 792–799. doi:10.1111/jvh.12393
   PubMed Web of Science ®Google Scholar
• Aspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S. J., Dore, G. J., … Hellard, M. E. (2013). Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clinical Infectious Diseases, 57(Suppl 2), S80–S89. doi:10.1093/cid/cit306
   PubMed Web of Science ®Google Scholar
• Aspinall, E. J., Weir, A., Sacks-Davis, R., Spelman, T., Grebely, J., Higgs, P., … Hellard, M. E. (2014). Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. International Journal of Drug Policy, 25, 179–182. doi:10.1016/j.drugpo.2013.08.005
   PubMed Web of Science ®Google Scholar
• Batchelder, A. W., Peyser, D., Nahvi, S., Arnsten, J. H., & Litwin, A. H. (2015). “Hepatitis C treatment turned me around:” Psychological and behavioral transformation related to hepatitis C treatment. Drug and Alcohol Dependence, 153, 66–71. doi:10.1016/j.drugalcdep.2015.06.007
   PubMed Web of Science ®Google Scholar
• Bayoumi, A., Strike, C., Brandeau, M., Degani, N., Fischer, B., Glazier, R., … Zaric, G. (2012). Report of the Toronto and Ottawa supervised consumption assessment study, 2012. Toronto, ON. Retrieved from http://www.stmichaelshospital.com/pdf/research/SMH-TOSCA-report-sum.pdf
   Google Scholar
• Bolotin, S., Feld, J., Garber, G., Wong, W., Guerra, F., & Mazzulli, T. (2018). Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. PLOS ONE, 13(1), e0191184. doi:10.1371/journal.pone.0191184
   PubMed Web of Science ®Google Scholar
• Bruggmann, P., & Litwin, A. H. (2013). Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all. Clinical Infectious Diseases, 57(SUPPL.2), 56–61. doi:10.1093/cid/cit271
   Google Scholar
• Bruneau, J., Zang, G., Abrahamowicz, M., Jutras-Aswad, D., Daniel, M., & Roy, E. (2014). Sustained drug use changes after hepatitis c screening and counseling among recently infected persons who inject drugs: A longitudinal study. Clinical Infectious Diseases, 58(6), 755–761. doi:10.1093/cid/cit938
   PubMed Web of Science ®Google Scholar
• Canadian Public Health Association. (2004). A health care needs assessment of federal inmates in Canada. Canadian Journal of Public Health. Revue Canadienne de Sante Publique (Vol. 95). doi:10.2307/41994314
   Google Scholar
• Chung, R. T., Davis, G. L., Jensen, D. M., Masur, H., Saag, M. S., Thomas, D. L., … Wyles, D. L. (2015). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology, 62(3), . doi:10.1002/hep.27950
   Web of Science ®Google Scholar
• Corsi, D. J., Karges, W., Thavorn, K., Crawley, A., & Cooper, C. L. (2015). Influences of female sex on hepatitis C virus infection progression and treatment outcomes. European Journal of Gastroenterology & Hepatology. doi:10.1097/MEG.0000000000000567
   Web of Science ®Google Scholar
• Edlin, B. R., Kresina, T. F., Raymond, D. B., Carden, M. R., Gourevitch, M. N., Rich, J. D., … Cargill, V. A. (2005). Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 40 Suppl 5(Suppl 5), S276–S285. doi:10.1086/427441
   PubMedGoogle Scholar
• European Association for the Study of the Liver. (2015). EASL recommendations on treatment of hepatitis C 2015. Journal of Hepatology, 63, 199–236.
   PubMed Web of Science ®Google Scholar
• Fischer, B., Powis, J., Cruz, M. F., Rudzinski, K., & Rehm, J. (2008). Hepatitis C virus transmission among oral crack users: Viral detection on crack paraphernalia. European Journal of Gastroenterology & Hepatology, 20, 29–32. doi:10.1097/MEG.0b013e3282f16a8c
   PubMed Web of Science ®Google Scholar
• Gonzalez, S. A., Fierer, D. S., & Talal, A. H. (2017). Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection. Addictive Disorders & Their Treatment, 16(2), S1–S23. doi:10.1097/ADT.0000000000000104
   PubMedGoogle Scholar
• Grebely, J., Alavi, M., Micallef, M., Dunlop, A. J., Balcomb, A. C., Phung, N., … Dore, G. J. (2016a). Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS study. Addiction, 111(2), 311–319. doi:10.1111/add.13197
   PubMed Web of Science ®Google Scholar
• Grebely, J., Bruggmann, P., Treloar, C., Byrne, J., Rhodes, T., & Dore, G. J. (2015a). Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 26(10), 893–898. doi:10.1016/j.drugpo.2015.07.007
   PubMed Web of Science ®Google Scholar
• Grebely, J., Dore, G. J., Greenwald, R., Swan, T., Barua, S., & Taylor, L. E. (2016b). Hepatitis C virus treatment and persons who inject drugs. Annals of Internal Medicine, 164(3), 203. doi:10.7326/L15-0485
   PubMed Web of Science ®Google Scholar
• Grebely, J., Genoway, K. A., Raffa, J. D., Dhadwal, G., Rajan, T., Showler, G., … Fischer, B. (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93, 141–147. doi:10.1016/j.drugalcdep.2007.09.008
   PubMed Web of Science ®Google Scholar
• Grebely, J., Morris, M. D., Rice, T. M., Bruneau, J., Cox, A. L., & Kim, A. Y., .… InC Study Group. (2013a). Cohort profile: The international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. International Journal of Epidemiology, 42(6), 1649–1659. doi:10.1093/ije/dys167
   PubMed Web of Science ®Google Scholar
• Grebely, J., Oser, M., Taylor, L. E., & Dore, G. J. (2013b). Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels. Journal of Infectious Diseases, 207(SUPPL.1), 19–25. doi:10.1093/infdis/jis928
   PubMed Web of Science ®Google Scholar
• Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., & Bruneau, J., .… Users, I. N. for H. in S. (2015b). Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 26, 1028–1038. doi:10.1016/j.drugpo.2015.07.005
   PubMed Web of Science ®Google Scholar
• Hellard, M., Doyle, J., Sacks-Davis, R., Thompson, A., & McBryde, E. (2014). Eradication of hepatitis C infection: The importance of targeting people who inject drugs. Hepatology, 59(2), 366–369. doi:10.1002/hep.26623
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University Press. (1997). The Johns Hopkins adjusted clinical groups (ACG) system. Retrieved from http://acg.jhsph.org/
   Google Scholar
• Johnson, T. L., Toliver, J. C., Mao, L., & Oramasionwu, C. U. (2014). Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study. BMC Infectious Diseases, 14(1), 217. doi:10.1186/1471-2334-14-217
   PubMedGoogle Scholar
• Lazarus, L., Shaw, A., LeBlanc, S., Martin, A., Marshall, Z., & Weersink, K., .… Committee, for P. C. A. (2014). Establishing a community-based participatory research partnership among people who use drugs in Ottawa: The PROUD cohort study. Harm Reduction Journal, 11(26), 1–8. doi:10.1186/1477-7517-11-26
   PubMedGoogle Scholar
• Litwin, A. H., Harris, K. A., Nahvi, S., Zamor, P. J., Soloway, I. J., Tenore, P. L., … Arnsten, J. H. (2009). Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment, 37(1), 32–40. doi:10.1016/j.jsat.2008.09.009
   PubMed Web of Science ®Google Scholar
• Marshall, A. D., Saeed, S., Barrett, L., Cooper, C. L., Treloar, C., & Bruneau, J., .… (CanHepC), the C. N. on H. C. (2016). Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: A descriptive study. CMAJ Open, 4(4), E605. doi:10.9778/cmajo.20160008
   PubMedGoogle Scholar
• Martin, N. K., Foster, G. R., Vilar, J., Ryder, S., Cramp, M. E., Gordon, F., … Hickman, M. (2015). HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: Real world results and modelling of treatment impact. Journal of Viral Hepatitis, 22(4), 399–408. doi:10.1111/jvh.12338
   PubMed Web of Science ®Google Scholar
• Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., … Hickman, M. (2013). Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (Baltimore, Md.), 58(5), 1598–1609. doi:10.1002/hep.26431
   PubMed Web of Science ®Google Scholar
• Martin, N. K., Vickerman, P., Miners, A., Foster, G. R., Hutchinson, S. J., Goldberg, D. J., & Hickman, M. (2012). Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology, 55(1), 49–57. doi:10.1002/hep.24656
   PubMed Web of Science ®Google Scholar
• Mason, K., Dodd, Z., Sockalingam, S., Altenberg, J., Meaney, C., Millson, P., & Powis, J. (2015). Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support. International Journal of Drug Policy, 26(10), 1007–1013. doi:10.1016/j.drugpo.2015.04.012
   PubMed Web of Science ®Google Scholar
• Meyer, J. P., Moghimi, Y., Marcus, R., Lim, J. K., Litwin, A. H., Altice, F. L., … Haven, N. (2015). Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. The International Journal on Drug Polic, 26(10), 922–935. doi:10.1016/j.drugpo.2015.05.002
   PubMed Web of Science ®Google Scholar
• Millson, P., Leonard, L., Remis, R., Strike, C., & Challacombe, L. (2004). Injection drug use, HIV and HCV infection in Ontario- The evidence 1992–2004., Ontario. Retrieved from http://www.ohrdp.ca/wp-content/uploads/2013/05/Research_Report.pdf
   Google Scholar
• Milne, R., Price, M., Wallace, B., Drost, A., Haigh-Gidora, I., Nezil, F. A., & Fraser, C. (2015). From principles to practice: Description of a novel equity-based HCV primary care treatment model for PWID. International Journal of Drug Policy, 26(10), 1020–1027. doi:10.1016/j.drugpo.2015.07.009
   PubMed Web of Science ®Google Scholar
• Ministry of Health and Long-Term Care. (2017). Frequently asked questions for health care providers: Hepatitis C drug products. Retrieved from http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/notices/fq_exec_office_20170227_1.pdf
   Google Scholar
• Myers, R. P., Msc, M., Shah, H., Hpte, M., Burak, K. W., Cooper, C., … Mph, M. (2015). An update on the management of chronic hepatitis C: 2015 consensus guidelines from the Canadian association for the study of the liver. Canadian Journal of Gastroenterology and Hepatology, (1), 19–34.
   Web of Science ®Google Scholar
• Paterson, B., Hirsch, G., & Andres, K. (2013). Structural factors that promote stigmatization of drug users with hepatitis C in hospital emergency departments. International Journal of Drug Policy. doi:10.1016/j.drugpo.2013.01.008
   PubMed Web of Science ®Google Scholar
• Pauly, B., McCall, J., Browne, A. J., Parker, J., & Mollison, A. (2015). Toward Cultural Safety. Advances in Nursing Science, 38(2), 121–135. doi:10.1097/ANS.0000000000000070
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. (2013). Enhanced Surveillance of HIV, Hepatitis C and associated risk behaviors among people who inject drugs in Canada. Phase 2 Report.
   Google Scholar
• Remis, R. S. (2007). Modelling the incidence and prevalence of Hepatitis C infection and its sequelae in Canada. Public Health Agency of Canada, 1–52.
   Google Scholar
• Scott, N., Iser, D. M., Thompson, A. J., Doyle, J. S., & Hellard, M. E. (2016). Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. Journal of Gastroenterology and Hepatology, 31(4), 872–882. doi:10.1111/jgh.13223
   PubMed Web of Science ®Google Scholar
• Steele, L. S., Glazier, R. H., Lin, E., & Evans, M. (2004). Using administrative data to measure ambulatory mental health service provision in primary care. Medical Care, 42(10), 960–965.
   PubMed Web of Science ®Google Scholar
• Talal, A. H., Thomas, D. L., Reynolds, J. L., & Khalsa, J. H. (2017). Toward optimal control of hepatitis C virus infection in persons with substance use disorders. Annals of Internal Medicine, 10–12. doi:10.7326/M16-2887
   PubMed Web of Science ®Google Scholar
• Tyndall, M. W. (2015). Misplaced advocacy: What does better hepatitis C treatment really mean? Canadian Medical Association Journal, 187(15), 1111–1112. doi:10.1503/cmaj.150652
   Web of Science ®Google Scholar
• Van Boekel, L. C., Brouwers, E. P. M., Van Weeghel, J., & Garretsen, H. F. L. (2013). Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2013.02.018
   Web of Science ®Google Scholar
• Wagner, G., Ryan, G., Osilla, K. C., Bhatti, L., Goetz, M., & Witt, M. (2009). Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. AIDS Patient Care and STDs, 23(9), 715–725. doi:10.1089/apc.2009.0049
   PubMed Web of Science ®Google Scholar
• Wolfe, D., Luhmann, N., Harris, M., Momenghalibaf, A., Albers, E., Byrne, J., & Swan, T. (2015). Human rights and access to hepatitis C treatment for people who inject drugs. International Journal of Drug Policy, 26(11), 1072–1080. doi:10.1016/j.drugpo.2015.05.007
   PubMed Web of Science ®Google Scholar